Yahoo
NSE - Delayed Quote INR

Divi's Laboratories Limited (DIVISLAB.NS)

9,780.00 +116.00 (+1.20%)
At close: October 30 at 3:28:16 PM GMT+5:30
Chart Range Bar
Loading chart for DIVISLAB.NS
  • Previous Close 9,664.00
  • Open 9,680.00
  • Bid --
  • Ask --
  • Day's Range 9,621.50 - 9,865.00
  • 52 Week Range 5,647.50 - 9,865.00
  • Volume 1,027,168
  • Avg. Volume 538,050
  • Market Cap (intraday) 2.596T
  • Beta (5Y Monthly) 0.23
  • PE Ratio (TTM) 88.74
  • EPS (TTM) 110.21
  • Earnings Date Nov 7, 2026
  • Forward Dividend & Yield 30.00 (0.31%)
  • Ex-Dividend Date Jul 24, 2026
  • 1y Target Est 8,612.17

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

www.divislabs.com

11,565

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

DIVISLAB.NS
53.62%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

DIVISLAB.NS
47.56%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

DIVISLAB.NS
191.64%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

DIVISLAB.NS
95.77%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 30.8B
Earnings 9.02B
Profit Margin 29.29%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
10B
20B
30B
24.0%
26.0%
28.0%

Analyst Insights

View More

Analyst Price Targets

6,336.00 Low
8,612.17 Average
9,780.00 Current
11,700.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.05%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    112.3B

  • Net Income Avi to Common (ttm)

    29.25B

  • Diluted EPS (ttm)

    110.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    32.33B

  • Total Debt/Equity (mrq)

    0.04%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: